We are live on ! Find out more
IBER

Ibere Pharmaceuticals
IBER

Delisted

IBER was delisted on the 1st of March, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Ibere Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 47 → 0 (-47)

100% less capital invested

Capital invested by funds: $126M → $0 (-$126M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 47

Holders
–
Holders Change
-47
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
47
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
-$13.4M
2
MF
Magnetar Financial
Illinois
-$7.93M
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$7.23M
4
PAMP
Polar Asset Management Partners
Ontario, Canada
-$6.85M
5
AC
Aristeia Capital
Connecticut
-$6.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
CF
26
Cantor Fitzgerald
New York
– -$1.13M -112,050 Closed
Walleye Capital
27
Walleye Capital
New York
– -$1.11M -110,048 Closed
FTCM
28
Fir Tree Capital Management
New York
– -$828K -82,037 Closed
Walleye Trading
29
Walleye Trading
New York
– -$807K -80,000 Closed
WA
30
Whitebox Advisors
Minnesota
– -$759K -75,246 Closed
CSS
31
Cubist Systematic Strategies
Connecticut
– -$752K -74,547 Closed
WRBC
32
W.R. Berkley Corp
Connecticut
– -$698K -69,176 Closed
Janus Henderson Group
33
Janus Henderson Group
United Kingdom
– -$534K -52,917 Closed
LCM
34
Lynwood Capital Management
Ontario, Canada
– -$519K -51,400 Closed
Goldman Sachs
35
Goldman Sachs
New York
– -$515K -50,995 Closed
HIM
36
HGC Investment Management
Ontario, Canada
– -$495K -49,023 Closed
DMKJ
37
David M. Knott Jr
– -$363K -36,000 Closed
SAM
38
Silverback Asset Management
North Carolina
– -$303K -30,000 Closed
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
– -$296K -29,367 Closed
WAM
40
Wolverine Asset Management
Illinois
– -$291K -28,841 Closed
Capstone Investment Advisors
41
Capstone Investment Advisors
New York
– -$252K -25,000 Closed
ETH
42
Exos TFP Holdings
New York
– -$230K -22,792 Closed
DIG
43
DeepCurrents Investment Group
New York
– -$179K -17,730 Closed
DFCM
44
Dark Forest Capital Management
Puerto Rico
– -$157K -15,574 Closed
RCM
45
Robinson Capital Management
Michigan
– -$96.4K -9,557 Closed
CS
46
Clear Street
New York
– -$16K -1,543 Closed
UBS Group
47
UBS Group
Switzerland
– -$5.49K -544 Closed
1
2

IBER Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q1 2023, worth a combined $0 — down 100% from $126M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of IBER and 0 opened new positions — a net loss of 47 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Glazer Capital LLC, exiting entirely with an estimated $13.4M sold.

  • 0 institutional investors held Ibere Pharmaceuticals (IBER) as of Q1 2023, down from 47 in Q4 2022.
  • Funds reported $0 of Ibere Pharmaceuticals stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Ibere Pharmaceuticals positions in Q1 2023 and 47 closed out, a net change of -47 holders.
  • The largest Ibere Pharmaceuticals seller in Q1 2023 was Glazer Capital LLC, an estimated $13.4M sold.

Based on aggregated 13F filings for Q1 2023.